Results 181 to 190 of about 23,762 (225)
Some of the next articles are maybe not open access.
Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry, 2016Development of new drugs is a time-consuming, hugely expensive and an uncertain endeavor. The pharmaceutical industry is looking for cost-effective alternatives with reduced risks of drug failure. Validated target machinery along with established inhibitors indicates usefulness in drug design, discovery and further development. Folate metabolism, found
Arundhati Chandrashekhar, Lele +4 more
openaire +2 more sources
Generation of recombinant CHO(dhfr−) cell lines by single selection for dhfr+ transformants
Analytical Biochemistry, 1992In order to establish a mammalian cell expression system with a minimum of selection steps and a stable expression of microgram amounts of recombinant protein (human tissue-type plasminogen activator mutants and chimeric proteins) per 10(6) cells per day, we investigated Chinese hamster ovary cells and the dihydrofolate reductase-deficient Chinese ...
D, Wernicke, H, Will
openaire +2 more sources
DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents.
Giampaolo Barone +2 more
exaly +3 more sources
Contains fulltext : 49184.pdf (Publisher’s version ) (Open Access)Both use of sulphadoxine-pyrimethamine (SP) and SP-resistance of Plasmodium falciparum are increasing in sub-Saharan Africa. Mutations in the P.
Jonas Schreiber +2 more
exaly +2 more sources
We and others have previously shown that uncoupling of endothelial nitric oxide synthase (eNOS) induces oxidative stress in diabetes, contributing to endothelial dysfunction.
Yixuan Zhang, Hua Cai, Ji Youn Youn
exaly +3 more sources
Screening of DHFR-binding drugs by MALDI-TOFMS
Analytical and Bioanalytical Chemistry, 2008The class of antimetabolite chemotherapeutical agents has been used to treat cancers in humans for almost 50 years and gives significant results by binding dihydrofolate reductase (DHFR), a key enzyme in DNA synthesis. Therefore, finding new active compounds inhibiting DNA synthesis through their binding to DHFR is of prime interest.
Paul, Hannewald +2 more
openaire +2 more sources
Specificity of ribozyme designed for mutated DHFR mRNA
Biochemical Pharmacology, 1994When MOLT-3 human acute leukemia cells were exposed sequentially to trimetrexate (TMQ) and then to methotrexate (MTX), the cells became resistant to antifolate. We designated this subline MOLT-3/TMQ800-MTX10,000. This cell line was found to contain two point mutations in the dihydrofolate reductase (DHFR) gene: a T-->C transition at nucleotide 95 in ...
H, Kobayashi +3 more
openaire +2 more sources
Targeting DHFR in parasitic protozoa
Drug Discovery Today, 2005Parasitic apicomplexans are responsible for some of the most severe worldwide health problems, including malaria, toxoplasmosis and cryptosporidiosis. These parasites are characterized by a bifunctional enzyme, dihydrofolate reductase-thymidylate synthase (DHFR-TS), which has a crucial role in pyrimidine biosynthesis.
openaire +2 more sources
Characterization of Schistosoma mansoni Dihydrofolate Reductase (DHFR)
2020Dihydrofolate reductase (DHFR) is an essential enzyme for nucleotide metabolism used to obtain energy and structural nucleic acids. Schistosoma mansoni has all the pathways for pyrimidine biosynthesis, which include the thymidylate cycle and, consequentially, the DHFR enzyme.
Vitor Hugo B, Serrão +2 more
openaire +2 more sources
Phenoxypropoxybiguanides, Prodrugs of DHFR−Inhibiting Diaminotriazine Antimalarials
Journal of Medicinal Chemistry, 2001A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine WR-99210 (8s), have been prepared. Several of them, such as 5b (PS-33) and 5m (PS-26), maintain or exceed the in vivo activity of PS-15 while not requiring the use of highly regulated starting materials. The putative diaminotriazine metabolites of these new analogues (
N P, Jensen +7 more
openaire +2 more sources

